Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080614 | 0.95 | LTA4H (0.64) | LTA4HTSHRNR5A1TP53PLA2G4B | |
| SCHEMBL6827504 | 0.95 | LTA4H (0.64) | LTA4HTSHRNR5A1TP53PLA2G4B | |
| SCHEMBL3073483 | 0.95 | LTA4H (0.64) | LTA4HTSHRNR5A1TP53PLA2G4B | |
| SCHEMBL7282685 | 0.95 | LTA4H (0.64) | LTA4HTSHRNR5A1TP53PLA2G4B | |
| SCHEMBL2121391 | 0.94 | LTA4H (0.53) | LTA4HTSHRCA12CA1CA2 | |
| SCHEMBL2120179 | 0.90 | NR5A1 (0.58) | LTA4HTSHRCA12CA1CA2 | |
| SCHEMBL2121574 | 0.89 | NR5A1 (0.61) | LTA4HTSHRNR5A1TP53PLA2G4B | |
| SCHEMBL3458574 | 0.89 | NR5A1 (0.61) | LTA4HTSHRNR5A1TP53PLA2G4B | |
| SCHEMBL1958536 | 0.89 | NR5A1 (0.61) | LTA4HTSHRNR5A1TP53PLA2G4B | |
| SCHEMBL1960613 | 0.89 | NR5A1 (0.61) | LTA4HTSHRNR5A1TP53PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790744-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20050181984-A1 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY | 2005-08-18 | — | — | US | disclosed |
| US-6916784-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-6743777-B1 | TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20030220236-A1 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY | 2003-11-27 | — | — | US | disclosed |
| EP-0744405-B1 | Cyclic peptide antifungal agents | LILLY CO ELI (US) | 2003-07-16 | — | — | EP | disclosed |
| EP-0736541-B1 | Cyclic hexapeptide antifungal agents | LILLY CO ELI (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6384013-B1 | HETEROCYCLIC PEPTIDE FUNGICIDES | ELI LILLY AND COMPANY | 2002-05-07 | — | — | US | disclosed |
| US-5965525-A | FOR INHIBITING FUNGAL AND PARASITIC ACTIVITIES | ELI LILLY AND COMPANY (US) | 1999-10-12 | — | — | US | disclosed |
| US-5932543-A | INHIBITING FUNGAL AND PARASITIC ACTIVITY | ELI LILLY AND COMPANY (US) | 1999-08-03 | — | — | US | disclosed |
| US-5652213-A | CYCLIC HEXAPEPTIDE FUNGICIDES, PARASITICIDES | ELI LILLY AND COMPANY (US) | 1997-07-29 | — | — | US | disclosed |
| US-5646111-A | Cyclic peptide antifungal Agents | ELI LILLY AND COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996037510-A1 | CYCLIC PEPTIDE ANTIFUNGAL AGENTS | ELI LILLY AND COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |
| EP-0744405-A2 | Cyclic peptide antifungal agents | ELI LILLY AND COMPANY (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1996031228-A1 | CYCLIC PEPTIDE ANTIFUNGAL AGENTS | ELI LILLY AND COMPANY (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0736541-A1 | Cyclic hexapeptide antifungal agents | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| EP-0561639-A1 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 1993-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220236-A1 | Cyclic peptide antifungal agents and process for preparation thereof | NGLY1, HM13, PTMS | LTA4H 2129/4885TSHR 2226/4885CA12 4346/4885 |
| US-20050181984-A1 | Cyclic peptide antifungal agents and process for preparation thereof | NGLY1, PTMS, HM13 | LTA4H 2378/4885TSHR 1713/4885CA12 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.